Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Reports Q3 Revenue Rise

SAN FRANCISCO, Oct. 23 - Illumina today reported increased revenue for the third quarter of 2002.


The company said its total revenue was $3 million in the third quarter which ended September 29, up from $700,000 in the same quarter of 2001. Strong oligo sales and first material revenue for genotyping services contributed to the rise in revenue, according to the company.


Illumina reported a net loss of $7.6 million, or $.24 per share, in the third quarter 2002 compared to a net loss of $5.8 million, or $.19 per share, in the year-ago period.


R&D spending increased to $6.4 million compared to $5.2 million in the same period a year ago.


Illumina also reported $73.7 million in cash and investments at the end of September 2002.


Click here for more information.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.